NEW YORK, June 17, 2016 /PRNewswire/ --
On Thursday, June 16, 2016, the
NASDAQ Composite ended the trading session at 4,844.92, up 0.21%;
the Dow Jones Industrial Average advanced 0.53% to finish at
17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The
gains were broad based as seven out of nine sectors ended the
session in positive. Stock-Callers.com has initiated coverage on
the following equities: Geron Corporation (NASDAQ: GERN), Merrimack
Pharmaceuticals Inc. (NASDAQ: MACK), Alnylam Pharmaceuticals Inc.
(NASDAQ: ALNY), and CytRx Corporation (NASDAQ: CYTR). Learn more
about these stocks by accessing their free trade alerts at:
http://stock-callers.com/
On Thursday, shares in Menlo Park,
California-based clinical stage biopharmaceutical company,
Geron Corp., ended the session 0.37% higher at $2.70 with a total volume of 1.44 million shares
traded. The Company's shares have advanced 1.50% in the last three
months. The stock is trading 8.58% below its 50-day moving average.
Moreover, shares of Geron have a Relative Strength Index (RSI) of
39.35. Sign up and read the free notes on GERN at:
http://stock-callers.com/
On Thursday, shares in Cambridge,
Massachusetts headquartered biopharmaceutical company,
Merrimack Pharmaceuticals Inc., ended the day 0.32% higher at
$6.33 with a total volume of 915,824
shares traded. The stock is trading below its 50-day moving average
by 10.30%. Furthermore, shares of Merrimack Pharmaceuticals have an
RSI of 41.49. The complimentary notes on MACK can be downloaded in
PDF format at:
http://stock-callers.com/
Cambridge, Massachusetts
headquartered biopharmaceutical company, Alnylam Pharmaceuticals
Inc.'s stock lost 1.29% to close the day at $58.38 with a total volume of 837,979 shares
traded. The Company's shares have advanced 7.55% in the last one
month and 0.93% in the previous three months. The stock is trading
9.31% below its 50-day moving average. Additionally, Alnylam
Pharmaceuticals' stock has an RSI of 40.30. Register for free on
Stock-Callers.com and access the latest research on ALNY at:
http://stock-callers.com/
CytRx Corp. operates as a biopharmaceutical research and
development company specializing in oncology. The stock finished
Thursday's session 2.61% higher at $2.36 with a total volume of 538,396 shares
traded. Over the last one month and the previous three months, the
Company's shares have advanced 2.61% and 10.80%, respectively. The
stock is trading below its 50-day moving average by 17.71%. CytRx's
stock has an RSI of 38.53. Get free access to your trade alert on
CYTR at:
http://stock-callers.com/
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored
reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and
micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
SC has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and
reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by SC. SC is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither SC nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly
at:
Office Address: Clyde Offices, Second Floor, 48 West George Street,
Glasgow, U.K. -G2 1BP
Email: info@stock-callers.com
Phone number: +44 330 808 3765
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA